L858R, T790M, G719, and L861Q EGFR missense mutations and G12C KRAS missense mutation are FDA-recognized biomarkers predictive of response to an FDA-approved drug (level 1) reported in NSCLC (Table 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.